Contrasting Minerva Surgical (NASDAQ:UTRS) & Motus GI (NASDAQ:MOTS)

Motus GI (NASDAQ:MOTS) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Risk & Volatility

Motus GI has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 4.81, suggesting that its share price is 381% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Motus GI and Minerva Surgical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Motus GI	0	0	1	0	3.00
Minerva Surgical	0	0	0	0	N/A

Motus GI currently has a consensus target price of $28.88, suggesting a potential upside of 52,730.43%.

Profitability

This table compares Motus GI and Minerva Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	-3,239.75%	-1,731.08%	-115.99%
Minerva Surgical	N/A	N/A	N/A

Earnings & Valuation

This table compares Motus GI and Minerva Surgical’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$320,000.00	0.99	-$12.87 million	($15.64)	0.00
Minerva Surgical	$50.29 million	0.00	-$34.11 million	($8.21)	N/A

Motus GI has higher earnings, but lower revenue than Minerva Surgical. Motus GI is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

20.1% of Motus GI shares are held by institutional investors. 0.3% of Motus GI shares are held by company insiders. Comparatively, 8.5% of Minerva Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Minerva Surgical beats Motus GI on 8 of the 11 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.